Comparison of cardiovascular outcomes in patients with diabetes treated with tirzepatide versus semaglutide: a multi-institutional analysis

Back

ESC Professional Premium Access

Comparison of cardiovascular outcomes in patients with diabetes treated with tirzepatide versus semaglutide: a multi-institutional analysis

Session: Diabetes as a risk factor for heart disease

Topic: Diabetes and the Heart

Speaker: Doctor M. Cervantes (Dallas, US)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Matthew Cervantes

Baylor University Medical Center, Dallas (United States of America)

0 follower

8 more presentations in this session

Prediction of cardiovascular risk in patients type 2 diabetes using the SCORE2-Diabetes risk score

Speaker: Associate Professor M. Cavender (Chapel Hill, US)

DNA methylation in the TXNIP gene is associated with type 2 diabetes in Pacific Peoples living in NZ

Speaker: Mr S. Gibbs (Christchurch, NZ)

Prognostic implications of right and left atrial strain in diabetes mellitus without coronary artery diseases.

Speaker: Professor M. Matshela (Durban, ZA)

Subgroup analysis of diabetes in COVID-positive revascularized patients: implications for clinical management

Speaker: Doctor Z. Alimli (Baku, AZ)

Lipid management among very-high-risk patients with atherosclerotic cardiovascular disease and type 2 diabetes

Speaker: Doctor S. Shoji (Durham, US)

Access the full session

Diabetes as a risk factor for heart disease

Speakers: Doctor M. Cervantes, Associate Professor M. Cavender, Mr S. Gibbs, Professor M. Matshela, Doctor Z. Alimli...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources